Fujisawa S, Maruta A, Ogawa K, Sakai R, Taguchi J, Tomita N, Kodama F, Sasaki S, Fukawa H, Murata T
Department of Hematology and Chemotherapy, Kanagawa Cancer Center.
Rinsho Ketsueki. 1995 Feb;36(2):91-7.
A retrospective analysis was performed on forty nine elderly (34 males and 15 females) patients aged 65 years or more (median age 73, range 65-82) with acute non-lymphocytic leukemia (ANLL). Patients were studied to examine factors according to age group (65-69 years, 70-74, 75-79 and 80 or over), respectively. Patients were treated with either low dose Ara-C therapy or BHAC-DMP therapy according of the choice of their attending physicians. Complete remission (CR) was obtained in 20 of 49 patients (43%), and in 6 of 14 patients (43%) aged 65-69, in 8 of 18 (44%) aged 70-74, in 5 of 12 (42%) aged 75-79 years and in 1 of 3 (33%) aged 80 or over, respectively. The median survivals of these groups were 263, 298, 260, 168.5 and 38.5 days, respectively. Multivariate analysis revealed that the achievement of CR was associated with normal karyotype, and serum GOT level < or = 30 mu/ml and GPT < or = 40 mu/ml. Prolonged survival was related to the achievement of CR. The results indicated that liver function before chemotherapy was an important prognostic factor.
对49例年龄在65岁及以上（中位年龄73岁，范围65 - 82岁）的老年急性非淋巴细胞白血病（ANLL）患者（34例男性，15例女性）进行了回顾性分析。根据年龄组（65 - 69岁、70 - 74岁、75 - 79岁和80岁及以上）分别研究患者的相关因素。根据主治医生的选择，患者接受低剂量阿糖胞苷治疗或BHAC - DMP治疗。49例患者中有20例（43%）获得完全缓解（CR），其中65 - 69岁的14例患者中有6例（43%），70 - 74岁的18例中有8例（44%），75 - 79岁的12例中有5例（42%），80岁及以上的3例中有1例（33%）。这些组的中位生存期分别为263天、298天、260天、168.5天和38.5天。多因素分析显示，CR的实现与正常核型、血清谷草转氨酶（GOT）水平≤30μ/ml和谷丙转氨酶（GPT）≤40μ/ml相关。生存期延长与CR的实现有关。结果表明化疗前的肝功能是一个重要的预后因素。
